Clinically relevant drug-drug interactions (DDI) are a serious concern for any new drug development project. To better support capturing the multiple mechanisms of DDI potential using primary hepatocytes, we now offer Interaction Qualified Human Hepatocytes (Catalog HUCPI) which are characterized for 3 major mechanisms of DDI: transporter activity, enzyme activity, and induction potential, providing you with one product to meet more of your hepatocyte DDI study needs.
Use the same donor for basal clearance, transport, and induction studies
Actual rates of transport reported rather than relative rates for less ambiguity
Large lots mean fewer rounds of testing so you can focus on results
Prequalified in Lonza media for better reproducibility
Inducibility of enzyme activity for CYP3A4, CYP2B6, and CYP1A2
Inducibility of mRNA for CYP3A4, CYP2B6, CYP1A2, and CYP2C8 genes
Actual rate of uptake or efflux for OATP1B1/3, OCT1/2, NTCP, and BSEP** transporters
Differences in passive vs. active uptake for OATP1B1/3, OCT1/2, and NTCP transporters.
Basal metabolism for 8 CYPs, SULT, UGT, and aldehyde oxidase
Plated low-turnover clearance for CYP2C9, CYP2D6, and CYP3A4
Complementary thawing, plating, and maintenance medium available
> 5 million viable cells/vial
Drug-Drug interaction studies
Low clearance metabolism studies
Drug uptake and efflux
Short term cellular toxicity studies
Our qualification methods are modeled after recommendations from the FDA publication In Vitro Metabolism and Transporter Mediated Drug-Drug Interaction Studies Guidance for Industry (2017, http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm).
***BSEP efflux activity is measured using the method described in Jie Zhang, et al., Chemico-Biological Interactions, Volume 255, 2016, Pages 45-54
|Dimensions||1 × 1 × 1 in|
Sterile, cryopreserved vial containing >5 million cells